In recent years, increasing evidence has suggested that combining immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors can enhance the efficacy of cancer treatment, especially for patients who are resistant to monotherapy of ICIs. The gene discussed is BRAF; the disease is cancer.